Action Required: Password Reset on Next Login
As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.
To reset your password, please visit the Reset Password page.
We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Vbi Vaccines Inc.
Headquarters: Cambridge, MA, United States of America
Website: http://www.vbivaccines.com
Year Founded: 2001
Status: Public
Industry Sector: HealthTechnology
CEO: Jeff Baxter
Number Of Employees: 138
Enterprise Value: $38,503,800
PE Ratio: 0
Exchange/Ticker 1: NASDAQ:VBIV
Exchange/Ticker 2: N/A
Latest Market Cap: $14,300
BioCentury | Aug 3, 2023
Data Byte
July follow-on financings: argenx raised majority of month’s $2.1B total
Ten biopharmas raised a combined $2.1B in July, of which argenx was responsible for nearly $1.3B
BioCentury | May 2, 2023
Management Tracks
Azam named CEO at Inspirna
Plus: Day One promotes Blackman to head of R&D, and updates from Esperovax, Ring, Alladapt, Innoviva and more
BioCentury | Jul 14, 2022
Management Tracks
Cantrell joins Brii as CBO
Plus Chan Lee to be general counsel at BeiGene and updates from CytoDyn, Kezar, Anaveon, Fulcrum and more
BioCentury | Dec 3, 2021
Product Development
Dec. 2 Quick Takes: $109M series C for Acepodia
Plus Tune catches $40M series A from NEA, Emerson, and Astellas-Dyno, Omeros, Vir and more
BioCentury | Feb 2, 2021
Product Development
Feb. 2 Quick Takes: Immunovant tumbles as it pauses trial; plus BMS, Legend-J&J, Arcutis, Prothena, VBI, Travere, Concert and Adamas
Immunovant Inc. (NASDAQ:IMVT) lost 42% to $25.08 on Tuesday after announcing it was pausing trials of anti-FCRN mAb IMVT-1401 (batoclimab) due to elevated total cholesterol and LDL signals in the
BioCentury | Aug 29, 2020
Product Development
COVID-19 Quick Takes: FDA expands remdesivir EUA; plus Warp Speed, Abbott, Moderna-Japan, CanSino-Canada, BeiGene-Singlomics, Sinovac, UNC, Daiichi, Laurent
Remdesivir authorized for mild patientsFDA expanded an emergency use authorization for remdesivir to include all patients hospitalized with COVID-19. The antiviral from Gilead Sciences Inc.
BioCentury | Aug 27, 2020
Product Development
COVID-19 Quick Takes: FDA authorizes 15-minute, $5 antigen test from Abbott; plus updates from IDSA, CEPI, Novavax, VBI, Verndari, AZ, Fluidigm, Tyme
Abbott test cleared for rapid point-of-careAbbott Laboratories (NYSE:ABT) said FDA granted Emergency Use Authorization (EUA) to a 15-minute point-of-care COVID-19 antigen test that costs $5 and
BioCentury | Aug 8, 2020
Product Development
Novavax secures multicountry access to COVID-19 vaccine
Plus VBI’s vaccine, remdesivir manufacturing and Siemens’ serology tests
BioCentury | Jun 18, 2019
Clinical News
June 17 Clinical Quick Takes: VBI's HBV vaccine misses secondary endpoint, plus ArQule, Verastem and more
BioCentury | Dec 7, 2018
Company News
Brii expands in infectious via deals with Vir, VBI, WuXi Biologics
Items per page:
1 - 10 of 30